ALDER BIOPHARMACEUTICALS INC short interest in 2019
In 2019, ALDER BIOPHARMACEUTICALS INC's disclosed short interest ran from 18.28% of shares outstanding on 15 Jan 2019 to 11.28% on 15 Oct 2019, a change of -7.00 percentage points. The year's high was 20.12% on 28 Feb 2019 and its low 11.28% on 15 Oct 2019, averaging 17.75% across 19 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 31.68 days on 30 Aug 2019. Full history: ALDER BIOPHARMACEUTICALS INC.
Cite this page
By year: 2018 · 2019
2019 in figures
- Start of year
- 18.28% (15 Jan 2019)
- End of year
- 11.28% (15 Oct 2019)
- Change
- -7.00 pp
- High
- 20.12% (28 Feb 2019)
- Low
- 11.28% (15 Oct 2019)
- Average
- 17.75%
- Highest days to cover
- 31.68 (30 Aug 2019)
- SEC filings marked
- 6
Every report in 2019
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 15 Jan 2019 | 18.28% | 10.69 | |
| 31 Jan 2019 | 19.40% | 8.62 | |
| 15 Feb 2019 | 19.58% | 17.89 | |
| 28 Feb 2019 | 20.12% | 8.93 | 10-K filed, results (8-K) |
| 15 Mar 2019 | 18.93% | 12.76 | |
| 29 Mar 2019 | 18.86% | 16.90 | |
| 15 Apr 2019 | 19.18% | 13.91 | |
| 30 Apr 2019 | 15.72% | 12.72 | |
| 15 May 2019 | 16.91% | 11.40 | 10-Q filed, results (8-K) |
| 31 May 2019 | 16.19% | 16.57 | |
| 14 Jun 2019 | 15.89% | 20.84 | |
| 28 Jun 2019 | 18.45% | 12.00 | |
| 15 Jul 2019 | 17.96% | 21.93 | |
| 31 Jul 2019 | 18.17% | 17.28 | |
| 15 Aug 2019 | 18.82% | 22.30 | 10-Q filed, results (8-K) |
| 30 Aug 2019 | 19.18% | 31.68 | |
| 13 Sep 2019 | 19.88% | 23.25 | |
| 30 Sep 2019 | 14.41% | 1.22 | |
| 15 Oct 2019 | 11.28% | 2.50 |
See also: ALDER BIOPHARMACEUTICALS INC's full history · most shorted US stocks of 2019 · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.